Steven Cohen Vaxcyte, Inc. Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 245,317 shares of PCVX stock, worth $8.99 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
245,317
Previous 245,317
-0.0%
Holding current value
$8.99 Million
Previous $9.26 Million
-0.0%
% of portfolio
0.02%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding PCVX
# of Institutions
340Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$446 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$441 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$431 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$364 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$235 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.17B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...